Amanote Research
Register
Sign In
Human Medicines European Public Assessment Report (EPAR): Raloxifene Teva, Raloxifene, Osteoporosis, Postmenopausal, Date of Authorisation: 29/04/2010, Revision: 8, Status: Authorised
Case Medical Research
doi 10.31525/cmr-fb7cdc
Full Text
Open PDF
Abstract
Available in
full text
Date
April 9, 2019
Authors
Unknown
Publisher
Case Journals
Related search
Human Medicines European Public Assessment Report (EPAR): Aclasta, Zoledronic Acid, Osteoporosis,Osteitis Deformans,Osteoporosis, Postmenopausal, Date of Authorisation: 15/04/2005, Revision: 25, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): PritorPlus, Telmisartan / Hydrochlorothiazide, Hypertension, Date of Authorisation: 22/04/2002, Revision: 33, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Bronchitol, Mannitol, Cystic Fibrosis, Date of Authorisation: 13/04/2012, Revision: 13, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Xyrem, Sodium Oxybate, Cataplexy,Narcolepsy, Date of Authorisation: 13/10/2005, Revision: 29, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): NovoRapid, Insulin Aspart, Diabetes Mellitus, Date of Authorisation: 07/09/1999, Revision: 29, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Palonosetron Hospira, Palonosetron, Nausea,Vomiting,Cancer, Date of Authorisation: 08/04/2016, Revision: 4, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Pregabalin Pfizer, Pregabalin, Anxiety Disorders,Epilepsy, Date of Authorisation: 10/04/2014, Revision: 13, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Tadalafil Mylan, Tadalafil, Erectile Dysfunction, Date of Authorisation: 21/11/2014, Revision: 8, Status: Authorised
Case Medical Research
Human Medicines European Public Assessment Report (EPAR): Farydak, Panobinostat, Multiple Myeloma, Date of Authorisation: 28/08/2015, Revision: 6, Status: Authorised
Case Medical Research
